A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients.

Trial Profile

A multicentre randomised, double blind, active controlled, parallel group comparison of Nebivolol plus HCTZ and Irbesartan plus HCTZ in the treatment of isolated systolic hypertension in elderly patients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Oct 2016

At a glance

  • Drugs Hydrochlorothiazide/nebivolol (Primary) ; Irbesartan/hydrochlorothiazide
  • Indications Isolated systolic hypertension
  • Focus Therapeutic Use
  • Acronyms NEHIS
  • Sponsors Menarini
  • Most Recent Events

    • 22 Oct 2016 Results published in the Advances in Therapy
    • 15 Jun 2015 Primary efficacy endpoint 'change in systolic blood pressure (24-hour mean SBP)' has been met as per the abstract presented at 25th European Meeting on Hypertension and Cardiovascular Protection.
    • 15 Jun 2015 Results presented at the 25th European Meeting on Hypertension and Cardiovascular Protection.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top